MLL-rearranged leukemias—an update on science and clinical approaches
AC Winters, KM Bernt - Frontiers in pediatrics, 2017 - frontiersin.org
The mixed-lineage leukemia 1 (MLL1) gene (now renamed Lysine [K]-specific
MethylTransferase 2A or KMT2A) on chromosome 11q23 is disrupted in a unique group of …
MethylTransferase 2A or KMT2A) on chromosome 11q23 is disrupted in a unique group of …
Targeting an RNA-binding protein network in acute myeloid leukemia
RNA-binding proteins (RBPs) are essential modulators of transcription and translation
frequently dysregulated in cancer. We systematically interrogated RBP dependencies in …
frequently dysregulated in cancer. We systematically interrogated RBP dependencies in …
Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis
Transcription and pre-mRNA splicing are key steps in the control of gene expression and
mutations in genes regulating each of these processes are common in leukaemia,. Despite …
mutations in genes regulating each of these processes are common in leukaemia,. Despite …
Mubritinib targets the electron transport chain complex I and reveals the landscape of OXPHOS dependency in acute myeloid leukemia
I Baccelli, Y Gareau, B Lehnertz, S Gingras, JF Spinella… - Cancer cell, 2019 - cell.com
To identify therapeutic targets in acute myeloid leukemia (AML), we chemically interrogated
200 sequenced primary specimens. Mubritinib, a known ERBB2 inhibitor, elicited strong anti …
200 sequenced primary specimens. Mubritinib, a known ERBB2 inhibitor, elicited strong anti …
Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins
Mutations in genes encoding splicing factors (which we refer to as spliceosomal genes) are
commonly found in patients with myelodysplastic syndromes (MDS) and acute myeloid …
commonly found in patients with myelodysplastic syndromes (MDS) and acute myeloid …
HBO1 is required for the maintenance of leukaemia stem cells
L MacPherson, J Anokye, MM Yeung, EYN Lam… - Nature, 2020 - nature.com
Acute myeloid leukaemia (AML) is a heterogeneous disease characterized by transcriptional
dysregulation that results in a block in differentiation and increased malignant self-renewal …
dysregulation that results in a block in differentiation and increased malignant self-renewal …
Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells
Many cancers carry recurrent, change-of-function mutations affecting RNA splicing factors.
Here, we describe a method to harness this abnormal splicing activity to drive splicing factor …
Here, we describe a method to harness this abnormal splicing activity to drive splicing factor …
[HTML][HTML] KMT2A Rearrangements in Leukemias: Molecular Aspects and Therapeutic Perspectives
L Guarnera, M D'Addona, C Bravo-Perez… - International journal of …, 2024 - mdpi.com
KMT2A (alias: mixed-lineage leukemia [MLL]) gene mapping on chromosome 11q23
encodes the lysine-specific histone N-methyltransferase 2A and promotes transcription by …
encodes the lysine-specific histone N-methyltransferase 2A and promotes transcription by …
Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes
G Ehx, JD Larouche, C Durette, JP Laverdure… - Immunity, 2021 - cell.com
Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, mainly
because of the lack of actionable immune targets. Using an original proteogenomic …
because of the lack of actionable immune targets. Using an original proteogenomic …
MLL-AF9 expression in hematopoietic stem cells drives a highly invasive AML expressing EMT-related genes linked to poor outcome
V Stavropoulou, S Kaspar, L Brault, MA Sanders… - Cancer cell, 2016 - cell.com
To address the impact of cellular origin on acute myeloid leukemia (AML), we generated an
inducible transgenic mouse model for MLL-AF9-driven leukemia. MLL-AF9 expression in …
inducible transgenic mouse model for MLL-AF9-driven leukemia. MLL-AF9 expression in …